Introduction
In the early 1990s, the concept of replacing lost cardiomyocytes with cells injected into the infarcted myocardium was pioneered by a handful of surgical and basic-research groups.
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In rodent models, transplanted cardiomyocytes from donor animals were shown to persist, integrate, and improve heart function, but there was no clinically usable source of human cells. Attention increased when skeletal myoblasts, readily available in man, were shown to engraft in cryoinjured rodent myocardium, 2 and excitement culminated when subpopulations of murine bone marrow (BM) progenitor cells of primarily hematopoietic lineage were shown to improve postinfarct heart function by inducing neovascularization 3 and presumably also by de novo formation of contractile tissue. 4 Compared with other completely novel therapeutic concepts, cardiac cell therapy then managed the transition from bench to bedside and commercialization attempts in an extremely short period of time. 5 Numerous clinical studies involving many thousands of patients have been, or are still being, conducted utilizing some form of cell transplantation into damaged myocardium. The first trials were done in small patient cohorts and showed feasibility, safety, and in some cases, evidence of efficacy.
irregularities positively correlated with magnitude of the reported increase in heart function, 8 while publications with no or few discrepancies mostly reported little or no therapeutic effect. Although the philosophy of metascience has been questioned, 9 the publication raised serious questions about the quality of some of the clinical research conducted so far in this field.
Skeletal Myoblasts
Quiescent satellite cells are found beneath the basal lamina of skeletal myofibers. In response to injury, they re-enter the cell cycle and give rise to proliferating myoblasts, which in turn differentiate, fuse, and repair damaged muscle. In the 1990s, several groups reported that skeletal myoblasts transplanted into cryodamaged or infarcted rodent myocardium survive and induce an improvement of left ventricular (LV) function.
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These findings led to clinical trials testing the safety of autologous skeletal myoblast transplantation in patients undergoing coronary artery bypass grafting (CABG) surgery after myocardial infarction (MI). 10, 11 The results of these studies did not suggest a therapeutic benefit with regard to ejection fraction or survival. Instead, in the case of the MARS trial, an increased incidence of ventricular arrhythmias led to premature termination of the trial. 10 The cause was traced back to insufficient electromechanical coupling of transplanted myoblasts with host cardiomyocytes, attributable to a lack of expression of the gap junction protein connexin 43. 12 In animal studies, overexpression of connexin 43 in skeletal myoblast prior to transplantation was protected from ventricular arrhythmias, but clinical application of these modified cells has not been investigated. 13 Today, few groups still pursue the concept of using skeletal muscle progenitors for heart repair in experimental models, for instance, in the form of cell sheets applied to the surface of the heart. 14 Indeed, a recent clinical pilot trial in patients with ischemic cardiomyopathy suggested hemodynamic improvements after stand-alone epicardial implantation of skeletal myoblast sheets. , these findings sparked an immense interest in BM-MNCs, and within few months of the initial publication, the first results from human trials were published. 5 A variety of clinical phases II and III trials were followed with varying and sometimes contradictory results. For example, the REPAIR-AMI 18-20 trial showed a beneficial effect on cardiac function and a reduction of cardiac events, but the TIME and LateTIME studies 21, 22 could not detect any recruitment of transplanted cells to the infarcted myocardium or improvement in ventricular function when investigating different time points and concentrations of BM-MNC injections postMI. In the majority of the trials, BMMNCs were delivered intracoronary in patients with (sub) acute MI, but the specifics regarding cell preparation, dose, and timing vary greatly (►Table 1). Several meta-analyses of those trials suggested an overall slightly higher LV ejection fraction (LVEF) at follow-up in cell-treated patients, but, as in any metaanalysis, publication bias cannot be ruled out, and the association between incremental changes in contractility and improvements in heart failure symptoms and survival remains unclear. 23 Disconcertingly, the meta-analysis by Nowbar et al showed that the increase in ejection fraction after BM cell therapy positively correlates with the number of discrepancies found in the published reports. 8 Furthermore, the studies with no or few discrepancies were not able to show any benefit regarding the efficacy end points of their respective trials. In 2012, investigators at the Queen Mary University London initiated an European Union (EU)-founded, investigator-driven multicenter, double-blinded phase III trial utilizing BM-MNCs in the setting of acute MI, aiming at enrolling 3,000 patients (BAMI, NCT01569178). The current recommendation of the task force of the European Society for Cardiology is to await the results of BAMI before initiating more trials or routinely incorporating BM-MNC therapy in the treatment of acute MI.
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Fewer trials were performed in patients with chronic ischemic heart disease (ischemic cardiomyopathy), but those are probably of higher relevance to the cardiac surgical community. Here, intracoronary, catheter-based intramyocardial and open surgical intramyocardial cells have been used, but the majority of groups lately focus on the latter two routes (►Table 1). Of the major trials investigating the effect of intracoronary or transendocardial injection of BM-MNCs, the ESPCAPE trial did report significant improvement of survival, improvement of cardiac function, and symptomatic relieve in patients receiving BM-MNCs. 25 Currently Several commercial providers of BM-MNC-based cell products or respective equipment have been or are still being involved in clinical trials for chronic ischemic disease. For instance, Celyad evaluated the benefit of preconditioning BM-MNCs with a proprietary cocktail for cardiogenic priming in patients with ischemic cardiomyopathy (C-CURE, CHART-1, and CHART-2 trials [►Table 1]). 26, 27 Initially, C-CURE demonstrated feasibility, safety, and improvement of LV function and symptoms compared with the placebo group, 26 but the phase III studies CHART-1 and CHART-2 failed to meet their respective end points. 28 Vericel Corp. uses a proprietary bioreactor system for expansion of BM-MNC, yielding a cell product with enhanced proportions of CD90þ stromal cells and an enrichment of "alternately activated CD45 þ CD14þ autofluorescent macrophages." 29, 30 The initial IMPACT-DCM (surgical cell injection) and CATHETER-DCM (NOGA-guided catheter delivery) trials in patients with ischemic and nonischemic cardiomyopathies were followed by the IxCell-DCM trial (►Table 2).
Here, a reduction in a composite end point of cardiovascular events was recently reported, but there were no significant changes in LVcontractile function compared with placebo, 31 so that the cause of the lower event rate remains elusive. Another concept is the intramyocardial transplantation of BM cells enriched for HSC markers CD34 or CD133 (►Tables 2 and 3). Here, antibodies attached to magnetic beads are used for cell isolation. In the surgical setting, autologous CD34þ BM cells were transplanted intramyocardially at the time of bypass surgery in small-scale trials, but little is known about phase III-equivalent follow-up studies.
32 Similarly, catheter-based injection of naïve CD34þ cells has largely been abandoned and only one randomized placebo-controlled study was able to demonstrate reduction in refractory angina after transendocardial injections. 33 A larger body of data are available on intramyocardial transplantation of CD133þ cells, an antigen that was considered to reflect a more immature population of HSCs with greater plasticity (►Table 3). A dose-escalation pilot study demonstrated feasibility and safety of CD133þ cell injection in conjunction with CABG surgery, 34 and controlled trials showed a significantly higher gain in LVEF after CABG and CD133þ cell transplantation than after CABG alone. 35 However, a subsequent randomized, placebo-controlled, doubleblinded trial failed to show any evidence of improved global LV function. 36 Nevertheless, the concept was still pursued in the surgical community, with a good clinical practice (GCP)-standard multicenter trial in Germany being terminated early.
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Meta-analyses including clinical cell therapy trials in chronic ischemic heart disease underscored the heterogeneity in outcome, 38 and are prone to publication bias due to preferential reporting of "positive" outcomes.
Mesenchymal Stromal Cells MSCs and Immune System
MSCs are the most extensively studied candidate for cell therapy and can be isolated from wide variety of adult tissues. Although it has become clear that MSC properties vary greatly depending on their source tissue and ex vivo culture conditions, minimal defining characteristics have been established. These include the expression of CD90, CD105, CD73, and CD44, colony formation in cell culture, and the capacity to differentiate into adipocytes, chondrocytes, and osteocytes in vitro. 39 In vivo, MSCs appear to arise from cells in the vicinity of small blood vessels (perivascular cells). 40 A host of biologic functions has been attributed to MSC. It is well established that they interact with immune cells by secreting cytokines such as interleukin-6, indoleamine 2,3 dioxygenase, prostaglandin E2, Granulocytemacrophage colony-stimulating factor, and transforming growth factor-β2. 41 Their capability in inhibiting macrophage polarization, 42 modulating neutrophil activity and function, 
MSCs and Myocardium
MSCs secrete angiogenic cytokines such as vascular endothelial growth factor (VEGF) promoting neovascularization and form vascular-like networks in in vitro assays and in vivo models. 46 In models of MI, MSCs exert an antiapoptotic effect, 47 promote angiogenesis, 48 and influence the homing of circulating endothelial progenitor cells via the secretion of (stromal cell-derived factor 1) SDF-1. 49 Other potential mechanisms are the activation of endogenous cardiac stem cells 50 and the prevention of the adverse ventricular There are currently two larger randomized and placebo controlled trials underway (CONCERT-HF and CardiAMP Heart Failure Trial). It remains to be seen whether the results will be as disappointing as those of trials using BM-MNCs. Abbreviations: þ, study results posted/published; AMI, acute myocardial infarction; ANR, active, not recruiting; C, trial completed; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; CPC, cardiac progenitor cells; DB, double blinded; DE, dose escalation; DI-CMP, drug induced cardiomyopathy; HF, heart failure; ICI, intracoronary injection; ICM, ischemic cardiomyopathy; IMI, intramyocardial injection; LVEF, left ventricular ejection fraction; MC, multicenter study; MNC, mononuclear cell; MSC, mesenchymal stromal cell; Np, no placebo; NYHA, New York Heart Association; OL, open label; PC, placebo controlled; PCI, percutaneous intervention; Pts, patients; Ra, randomized; RaSC, randomized against standard care; SB, single blinded; SGA, single group assignment; SU, status of trial unknown for more than 2 years; T, trial terminated; TEndo, transendocardial injection. The placenta is also a source of large doses of neonatal cells with high proliferation capacity, doubtless immunomodulatory, and proangiogenic, but controversial myogenic capacity. Epithelial cells from the fetal side of the amniotic membrane were believed to retain embryonic stem cell characteristics (OCT-4, Nanog, TRA-1-60, TRA-1-81, and SSEA-3 expression), and did show some cardioregenerative effects in experimental models, 73 as did MSCs derived from amniotic membrane stroma, both with potential allogenic applicability. 74 Outcomes of systematic clinical trials, however, have not been reported.
Resident Cardiac Progenitor Cells
The dogma of the mammalian heart having no intrinsic cardiomyocyte regeneration capacity has been challenged by reports that adult cardiomyocytes are capable of mitosis and the identification of resident cardiac progenitor cells (CPCs). (►Table 2). There were no safety issues, and some improvements in regional contractility and/or global LV function were reported. However, the design of one of the trials has been subject to criticism. 34 Another interesting approach is the combination of CPCs and MSCs in the CONCERT-HF study that is currently recruiting patients (►Table 2) because preclinical data suggested that a synergetic effect in improvement of cardiac remodeling can be achieved.
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In our institution, a different cell product obtained from endomyocardial biopsy tissue was developed. The "CardAP" cells are isolated via outgrowth followed by expansion in dedicated media. 84 They have no cardiomyocyte differentiation potential but exert potent immunomodulatory effects and have been designed for use in nonischemic, dilated of inflammatory heart disease. 85 Clinical pilot studies are currently being prepared.
Exosomes
Exosomes are microvesicles secreted from various kinds of somatic cells that contain numerous proteins and nucleic acids, that is, miRNA. They are collected from the media of naïve or stimulated cells and enriched by centrifugation. In various experimental settings, exosomes were shown to be as effective in preventing postinfarct deterioration of heart function as their viable and intact source cells. 86 Using exosomes instead of viable cell products may simplify therapeutic applications and lower regulatory hurdles. In a recent large animal study, exosomes were only therapeutic when injected directly into the myocardium, while intracoronary exosomes when ineffective. 87 Current research aims at producing standardized exosome-based products from universal source cells, so that an off-the-shelf product with defined characteristics can be applied clinically.
Comment
For approximately 20 years, cell-based applications for ischemic and other kinds of heart disease have been considered the future of heart failure therapy. A lot has been learned about somatic progenitor cell biology, myocardial cell behavior, and interactions between heart and BM. Rather than truly regenerating, that is, recreating, de novo contractile cells, somatic cell therapy was found to act via a wide range of secondary mechanisms such as supporting neovascularization, increasing host cardiomyocyte resistance to ischemia, modulation of tissue inflammation, and influencing fibrous tissue remodeling. Those are most likely mediated by secreted proteins, nucleic acids, or microvesicles containing both. A tremendous amount of resources went into this field, but little was achieved in terms of robust, relevant, and reproducible benefit for patients. More than 15 years after the first BM cell transplantations in the infarcted heart, clinical trials that showed no impact on LV function are still considered to successfully demonstrate feasibility and safety. Many of the initial proponents of cardiac cell therapy have entirely abandoned that field of research, while others argue that better patient selection, tailored approaches instead of "one size fits all," modification of cells or combination with drugs, biomaterials, or other cells will finally bring clinical success. Commercial providers of cell therapies for heart disease (and many other diseases) have flourished (i.e., as Cytori Therapeutics, Osiris Therapeutics). Many have redirected their activities, but others continue to offer their products to patients with little, if any scientific basis. In most of the industrialized countries, tightened regulations such as the EU Regulation No 1394/2007 have put a stop to many of those merely profit-oriented activities. On the contrary, the same regulations have made it extremely difficult to organize and conduct serious investigator-initiated clinical research in this field. Despite findings suggesting that postnatal mammalian myocardium has both baseline and inducible myocyte turnover, 75 the adult human heart is an organ that refuses to regenerate much. A lot more than simply injecting cells derived from other tissues will be needed to change that.
